重组黄热病毒E蛋白结构域Ⅲ作为亚单位疫苗的抗原性和免疫原性

目的：表达纯化黄热病毒（YFV）囊膜蛋白（E蛋白）结构域Ⅲ,研究其作为亚单位疫苗预防YFV、日本脑炎病毒（JEV）感染的可能。方法：扩增YFVE蛋白结构域Ⅲ（YFDⅢ）的cDNA片段333bp,将其连接到原核表达载体pET-32a（＋）中,构建原核表达载体pET-YFDⅢ,转化感受态大肠杆菌Rosetta（DE3）,IPTG诱导表达重组YFDⅢ;用纯化的YFDⅢ免疫新西兰兔和BALB/c鼠,检测相关抗体滴度。结果：在大肠杆菌中可溶性表达了YFDⅢ融合蛋白,表达量约占菌体蛋白的50%;Western印迹及ELISA分析表明,纯化的YFDⅢ具有良好的抗原性和免疫原性;利用纯化的YFDⅢ免疫新西兰兔,获得了高达1∶4×105滴度的抗YFV抗体和1∶2×104滴度的抗JEV抗体;利用纯化的YFDⅢ免疫BALB/c鼠,获得了1∶7×104滴度的抗YFV抗体和1∶2×103滴度的抗JEV抗体。结论：重组YFDⅢ有较好的免疫原性,具有开发成亚单位疫苗的潜能。     

神经纤毛蛋白-1的原核表达及兔抗小鼠神经纤毛蛋白-1抗体免疫学活性的研究

目的:在原核系统中分段表达神经纤毛蛋白-1(Nrp1);将纯化的蛋白免疫家兔后获得特异的抗体,并将其应用于检测组织和细胞中Nrp1分子的表达。方法:提取BALB/c胎鼠脑组织总RNA,通过RT-PCR分段扩增获得Nrp1基因片段,将PCR产物插入表达载体pET28a( ),获得含5个Nrp1基因片段的重组质粒,在大肠杆菌BL21(DE3)中诱导蛋白表达并纯化;将纯化的重组蛋白免疫新西兰大白兔获得针对目的蛋白的特异性多克隆抗体;利用Nrp1特异性多抗检测胎鼠脑组织和HeLa细胞中Nrp1的表达。结果:在原核系统中分段表达了Nrp1蛋白,通过Ni-NTA纯化了Nrp1蛋白片段;纯化的Nrp1蛋白免疫新西兰大白兔获得了具有免疫活性的多抗;兔抗小鼠Nrp1特异性多抗可用于检测组织、真核细胞中Nrp1的表达。结论:应用原核系统成功地表达了Nrp1蛋白,兔抗小鼠Nrp1特异性多抗可用于免疫学检测Nrp1分子的表达。     

表达重组猪瘟病毒E290多肽的干酪乳杆菌口服免疫特性及诱导特异性CTL反应的研究

经PCR扩增获得约60bp编码猪瘟病毒T细胞表位E290多肽基因片段,克隆至表达载体pPG-VP2中VP2基因5′端上游,命名为pPG-VP2-E290,电转化干酪乳杆菌,构建了表达猪瘟病毒E290多肽的重组乳酸菌系统。口服免疫BALB/c鼠和新西兰兔,检测诱导小鼠和兔体内产生特异性抗猪瘟病毒E290多肽IgG水平,并对E290多肽的CTL活性进行检测,同时对免疫兔进行猪瘟病毒攻毒实验,检测E290多肽抗体对免疫兔的保护作用。构建的重组猪瘟病毒T细胞表位的干酪乳杆菌具有良好的免疫性,口服免疫后的小鼠和兔血清中均检测到了较高水平的抗E290多肽抗体IgG,且能诱导小鼠机体产生抗猪瘟病毒的特异性CTL反应,亦证实猪瘟病毒E290免疫兔能够抵抗猪瘟病毒的攻击。     

ORP4L 多克隆抗体的制备及其在蛋白质组学研究中的应用

目的:原核表达并纯化人氧化固醇结合蛋白相关蛋白4(ORP4L)肽段,制备兔抗人ORP4L多克隆抗体,并利用其进行蛋白质组学研究。方法:应用PCR技术扩增人ORP4L 382-485氨基酸(ORP4Lm)的基因序列并插入到PGEX-4T-1载体中,在大肠杆菌RosettaTM(DE3)中表达融合蛋白GST-ORP4Lm。利用所表达的融合蛋白中含有的GST标签进行亲和纯化。用所获得的纯化蛋白免疫新西兰大白兔,获得兔抗人ORP4L多克隆抗体。用Western blotting检测抗体免疫特异性。将亲和纯化后的抗体偶联到CNBr-actived sepharose beads上,利用免疫沉淀的方法,通过质谱仪分析鉴定可能与ORP4L存在相互作用的蛋白质。通过West-ern blotting进一步确证特异性的相互作用蛋白。结果:在大肠杆菌中表达并纯化了GST-ORP4Lm重组蛋白,用其免疫新西兰大兔,成功制备了相应兔源多克隆抗体,Western blotting证实该抗体可以特异识别内源性及外源性的ORP4L蛋白。质谱分析和Western blotting的结果表明所制备的多克隆抗体可以用于蛋白质组学研究。结论:利用重组的GST-ORP4Lm融合蛋白成功制备了有良好特异性的ORP4L多克隆抗体,并可将其用于ORP4L的蛋白组学研究。     

ORP4L多克隆抗体的制备及其在蛋白质组学研究中的应用水

目的：原核表达并纯化人氧化固醇结合蛋白相关蛋白4（ORP4L）肽段,制备兔抗人ORP4L多克隆抗体,并利用其进行蛋白质组学研究。方法：应用PCR技术扩增人ORP4L382-485氨基酸（ORP4Lm）的基因序列并插入到PGEX-4T—1载体中,在大肠杆菌RosettaTM（DE3）中表达融合蛋白GST-ORP4Lm。利用所表达的融合蛋白中含有的GST标签进行亲和纯化。用所获得的纯化蛋白免疫新西兰大白兔,获得兔抗人ORP4L多克隆抗体。用Western blotting检测抗体免疫特异性。将亲和纯化后的抗体偶联到CNBr-actived sepharosC beads上,利用免疫沉淀的方法,通过质谱仪分析鉴定可能与ORP4L存在相互作用的蛋白质。通过West—ernblotting进一步确证特异性的相互作用蛋白。结果：在大肠杆菌中表达并纯化了GST-ORP4Lm重组蛋白,用其免疫新西兰大兔．成功制备了相应兔源多克隆抗体,Western blotting证实该抗体可以特异识别内源性及外源性的ORP4L蛋白。质谱分析和Western blotting的结果表明所制备的多克隆抗体可以用于蛋白质组学研究。结论：利用重组的GST-ORP4Lm融合蛋白成功制备了有良好特异性的ORP4L多克隆抗体,并可将其用于ORP4L的蛋白组学研究。     

人乳头瘤病毒6b型E7蛋白的原核表达及多克隆抗体制备

进行人乳头瘤病毒6b型(Human papillomavirus type 6b,HPV6b)E7蛋白原核表达并制备其多克隆抗体。用已构建的pGEX-4T-2/HPV6bE7原核表达载体诱导表达大量可溶性融合蛋白GST-HPV6bE7,用Glutathione-Sepharose 4B亲和柱和凝血酶纯化获取HPV6b型E7蛋白。将纯化的E7蛋白免疫新西兰兔并纯化为多克隆抗体IgG。采用Western-Blot及免疫荧光法分析该抗体的效价及特异性。十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)分析显示,异丙基-β-D-硫代半乳糖苷(IPTG)诱导3～6h后pGEX-4T-2/HPV6bE7表达载体在大肠杆菌中高水平表达可溶性融合蛋白。纯化的E7蛋白免疫新西兰兔后可获得兔多克隆抗体IgG。经Western-Blot及免疫荧光鉴定,兔抗IgG具有高效价性和抗HPV6bE7蛋白特异性。获取纯化的HPV6b型E7蛋白具有较好的免疫原性,其免疫兔产生的多克隆抗体IgG效价高,特异性好,有望进一步用于HPV6b型的生物学功能研究和免疫学效应研究。     

抗Ⅰ型马立克氏病毒sorf2蛋白的多克隆抗体制备及其特异性鉴定

[目的]制备高效价鼠和兔抗Ⅰ型马立克氏病毒(Marek's disease virus,MDV) sorf2蛋白的多克隆抗体并对其特异性进行鉴定.[方法]以Ⅰ型MDV GX0101为模板,利用PCR扩增sorf2基因,分别克隆进原核表达载体pET-28a(+)和pET-32a(+)中,转化大肠杆菌BL21 (Rosetta),经异丙基硫代-β-D半乳糖苷(IPTG)诱导后进行融合蛋白的表达和纯化.用纯化的融合目的蛋白常规免疫6-8周龄Balb/c小鼠和成年新西兰大白兔,制备抗sorf2蛋白的多克隆抗体.用Western blot和间接免疫荧光试验鉴定多克隆抗体的特异性.[结果]Ⅰ型MDV的sorf2基因在原核表达载体中能够正确表达,免疫小鼠和兔后能获得与sorf2蛋白发生特异性反应的高效价的多克隆抗体.[结论]制备的抗sorf2蛋白的多克隆抗体能够特异的鉴定MDV sorf2基因缺失株,有效的区分MDV疫苗株HVT(FC-126)与Ⅰ型MDV毒株,用于临床MDV野毒的分离鉴定.     

拟南芥转录因子NF-YC的原核表达及多克隆抗体制备

采用PCR方法扩增NF-YC基因得到其全长cDNA序列,并将其克隆至原核表达载体pET-48b中,在大肠杆菌BL21中用IPTG诱导出分子量约为45 kD的融合蛋白,SDS-PAGE和Western blotting检测鉴定表达产物。利用亲和层析技术对融合蛋白进行纯化,纯化后的目的蛋白免疫新西兰兔制备多克隆抗体。间接ELISA检测抗体效价大于1 62 500,Western blotting结果显示,该抗体可特异性识别NF-YC蛋白。     

毕赤酵母分泌表达JEV prME蛋白及其形成病毒样颗粒的免疫原性鉴定

应用毕赤酵母分泌表达日本脑炎病毒(Japanese encephalitis virus,JEV)prME蛋白,鉴定其表达效果与免疫原性,以期为JEV亚单位疫苗的研制奠定基础。RT-PCR扩增JEV SA14-14-2株prME基因,将其连接到毕赤酵母表达载体pPICZa-A,分别获得pPICZa-prME和携带JEV Cap蛋白C末端19个Aa信号肽的pPICZa-SprME质粒。表达载体用PmeⅠ酶切线性化,通过电转化转入毕赤酵母X33并诱导发酵培养。利用SDS-PAGE和Western blotting鉴定酵母发酵上清中目的蛋白的表达情况。利用GE蛋白层析纯化柱纯化目的蛋白,利用电镜观察纯化前后的目的蛋白,将不同剂量纯化后的prME蛋白与弗氏佐剂混合以及定量纯化后的prME蛋白与不同剂量的核酸佐剂混合分别免疫4周龄小鼠,定期采血,ELISA检测被免小鼠血清的抗体水平,空斑减少试验测定抗体中和效价。SDS-PAGE结果表明毕赤酵母可以分泌表达完整的prME蛋白,目的蛋白在70–100 kDa之间;Western blotting结果显示分泌表达的prME蛋白具有良好的反应原性,进一步证明prME蛋白在酵母X33中以整体的形式分泌表达,没有发生水解切割。纯化目的蛋白,根据洗脱时间和体积表明其分子量大于1×10~6 Da,因此推断prME蛋白可能形成多聚化的颗粒。电镜观察发现直径30–50 nm的病毒样颗粒(Virus like particles,VLPs)。免疫试验结果表明,纯化后的重组蛋白10–15μg/只接种小鼠在3周后抗体达到高峰值,之后逐渐下降,免疫7周后小鼠血清仍可检测到JEV抗体。将prME VLPs以10μg/只的剂量与不同剂量的核酸佐剂配伍后接种小鼠,ELISA检测结果表明核酸佐剂可明显增强JEV prME VLPs免疫应答,免疫4周后小鼠血清的中和抗体效价为1∶80–1∶160。上述结果表明毕赤酵母表达JEV prME虽不能发生水解切割,但仍可形成VLP并诱导免疫小鼠产生较高水平中和抗体。     

支气管败血波氏杆菌皮肤坏死毒素的重组表达及其生物学特性

皮肤坏死毒素(DNT)是支气管败血波氏杆菌的主要致病因子之一.通过PCR分段扩增和克隆获得了全长4 356 bp的dnt基因,并利用pET-28a/BL21系统对其进行了融合表达.Western blotting检测结果表明,表达产物具有良好的免疫学活性.使用His-band purification kit纯化试剂盒纯化后,得到纯度为93.2％的融合蛋白His6-DNT.在乳鼠皮肤坏死试验中,表达产物His6-DNT和天然DNT均能导致乳鼠皮肤产生坏死性病变.在乳鼠皮肤坏死阻断试验中,兔抗His6-DNT血清能中和天然DNT使其失去对乳鼠的皮肤坏死毒性.试验结果表明,重组蛋白具有天然DNT的生物学毒性和免疫原性,所产生的抗体具有中和活性.文中所获得的重组DNT蛋白具有良好的生物学活性,为DNT的结构和功能研究奠定基础.     

Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection‐enhancing antibody response

Neutralizing antibodies induced by dengue virus (DENV) infection show viral infection‐enhancing activities at sub‐neutralizing doses. On the other hand, preimmunity against Japanese encephalitis virus (JEV), a congener of DENV, does not increase the severity of DENV infection. Several studies have demonstrated that neutralizing epitopes in the genus Flavivirus are mainly located in domain III (DIII) of the envelope (E) protein. In this study, chimeric premembrane and envelope (prM‐E) gene‐based expression plasmids of JEV and DENV1 with DIII substitution of each virus were constructed for use as DNA vaccines and their immunogenicity evaluated. Sera from C3H/He and ICR mice immunized with a chimeric gene containing DENV1 DIII on a JEV prM‐E gene backbone showed high neutralizing antibody titers with less DENV infection‐enhancing activity. Our results confirm the applicability of this approach as a new dengue vaccine development strategy.     

Inhibition of japanese encephalitis virus infection by flavivirus recombinant e protein domain III

Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus closely related to the human pathogens including yellow fever virus, dengue virus and West Nile virus. There are currently no effective antiviral therapies for all of the flavivirus and only a few highly effective vaccines are licensed for human use. In this paper, the E protein domain III (DIII) of six heterologous flaviviruses (DENV1-4, WNV and JEV) was expressed in Escherichia coli successfully. The proteins were purified after a solubilization and refolding procedure, characterized by SDS-PAGE and Western blotting. Competitive inhibition showed that all recombinant flavivirus DIII proteins blocked the entry of JEV into BHK-21 cells. Further studies indicated that antibodies induced by the soluble recombinant flavivirus DIII partially protected mice against lethal JEV challenge. These results demonstrated that recombinant flavivirus DIII proteins could inhibit JEV infection competitively, and immunization with proper folding flavivirus DIII induced cross-protection against JEV infection in mice, implying a possible role of DIII for the cross-protection among flavivirus as well as its use in antigens for immunization in animal models.     

Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization

The Flavivirus genus of the Flaviviridae family includes 70 enveloped single-stranded-RNA positive-sense viruses transmitted by arthropods. Among these viruses, there are a relevant number of human pathogens including the mosquito-borne dengue virus (DENV), yellow fever virus (YFV), Japanese encephalitis virus (JEV) and West Nile virus (WNV), as well as tick-borne viruses such as tick-borne encephalitis virus (TBEV), Langat virus (LGTV) and Omsk hemorrhagic fever (OHFV). The flavivirus envelope (E) protein is a dominant antigen inducing immunologic responses in infected hosts and eliciting virus-neutralizing antibodies. The domain III (DIII) of E protein contains a panel of important epitopes that are recognized by virus-neutralizing monoclonal antibodies. Peptides of the DIII have been used with promising results as antigens for flavivirus serologic diagnosis and as targets for immunization against these viruses. We review here some important aspects of the molecular structure of the DIII as well as its use as antigens for serologic diagnosis and immunization in animal models.     

Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection

The domain III of the West Nile virus (WNV) envelope glycoprotein (E) was shown to serve as virus attachment domain to the cellular receptor, and neutralizing Abs have been mapped to this specific domain. In this study, domain III of the WNV E protein (WNV E DIII) was expressed as a recombinant protein and its potential as a subunit vaccine candidate was evaluated in BALB/C mice. Immunization of WNV E DIII protein with oligodeoxynucleotides (CpG-DNA) adjuvant by i.p. injection was conducted over a period of 3 wk. The immunized mice generated high titer of WNV-neutralizing Abs. Murine Ab against WNV E DIII protein was also capable of neutralizing Japanese encephalitis virus. The IgG isotypes generated were predominantly IgG2a in the murine sera against the recombinant protein. Splenocyte cultures from the mice coadministrated with WNV E DIII protein and CpG secreted large amounts of IFN-gamma and IL-2 and showed proliferation of T cells in the presence of WNV E DIII protein. Overall, this study highlighted that recombinant WNV E DIII protein delivered in combination with CpG adjuvant to mice generated a Th1 immune response type against WNV and can serve as a potential vaccine to prevent WNV infection.     

Characterization of the tammar wallaby (Macropus eugenii) whey acidic protein gene; new insights into the function of the protein

SUMMARY Whey acidic protein (WAP) belongs to a family of four disulfide core (4-DSC) proteins rich in cysteine residues and is the principal whey protein found in milk of a number of mammalian species. Eutherian WAPs have two 4-DSC domains, whereas marsupial WAPs are characterized by the presence of an additional domain at the amino terminus. Structural and expression differences between marsupial and eutherian WAPs have presented challenges to identifying physiological functions of the WAP protein. We have characterized the genomic structure of tammar WAP (tWAP) gene, identified its chromosomal localization and investigated the potential function of tWAP. We have demonstrated that tWAP and domain III (DIII) of the protein alone stimulate proliferation of a mouse mammary epithelial cell line (HC11) and primary cultures of tammar mammary epithelial cells (Wall-MEC), whereas deletion of DIII from tWAP abolishes this proliferative effect. However, tWAP does not induce proliferation of human embryonic kidney (HEK293) cells. DNA synthesis and expression of cyclin D1 and cyclin-dependent kinase-4 genes were significantly up-regulated when Wall-MEC and HC11 cells were grown in the presence of either tWAP or DIII. These data suggest that DIII is the functional domain of the tWAP protein and that evolutionary pressure has led to the loss of this domain in eutherians, most likely as a consequence of adopting a reproductive strategy that relies on greater investment in development of the newborn during pregnancy.     

登革病毒四型联合重组包膜蛋白III区的表达和免疫原性鉴定

登革热在全球范围内广泛流行,但是目前为止却仍然没有疫苗上市,疫苗的开发迫在眉睫。抗体依赖增强感染效应是登革病毒疫苗开发中遇到的一个瓶颈问题。研究表明登革病毒的包膜蛋白III区能够介导中和抗体产生,且诱导产生较少的交叉抗体或无交叉抗体,能够大大减弱抗体依赖增强感染效应,因而是登革热重组蛋白疫苗的首选靶标。通过酵母密码子优化后合成同时包含4种血清型登革病毒包膜蛋白III区的四价联合DV EDIII蛋白序列,随后构建酵母表达质粒,并获得酵母表达菌株,经诱导后四联DV EDIII蛋白获得高效表达。通过Western blot、ELISA检测及蛋白质免疫原性鉴定,结果表明登革病毒四联DV EDIII蛋白表达质粒构建成功,重组蛋白在毕赤酵母获得高效表达,免疫小鼠后能够介导产生较高水平的血清效价。这表明已获得了能引起有效免疫反应的四型登革病毒EDIII蛋白,为登革病毒疫苗的研究提供了良好的基础。     

A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites

The envelope (E) protein of Japanese encephalitis virus (JEV) is associated with viral binding to cellular receptors, membrane fusion, and the induction of protective neutralizing-antibody responses in hosts. Most previous studies have not provided detailed molecular information about the spatial configuration of the functional epitopes on domain III of the E protein. Here site-directed mutagenesis was performed to demonstrate that the functional epitope determinants at Ser331 and Asp332 on domain III of the JEV E protein interacted with neutralizing monoclonal antibody (MAb) E3.3. Bacterial expression of the recombinant Fab E3.3 confirmed the molecular interactions of Arg94 in complementary determining region H3 with Ser331 and Asp332 on domain III. This study elucidates the detailed molecular structures of the neutralizing epitope determinants on JEV domain III, which can provide useful information for designing new vaccines.     

Identification and characterization of Japanese encephalitis virus envelope protein gene from swine

Aims: Identification and characterization of Japanese encephalitis virus (JEV) envelope protein gene from swine. Methods and Results: Genomic RNA was separated from JEV isolated strain Henan‐09‐03, and used as templates for cDNA synthesis of E gene. The cDNA of E gene was amplified by RT‐PCR and cloned into the pMD19‐T‐Vector and confirmed by sequencing. The cloned gene was then subcloned into the pET‐32a and was introduced into Escherichia coli BL21 (DE3) for expression. The E protein was purified by Ni chelating column‐based affinity chromatography. The molecular weight of expressed protein was about 50 kDa. Compared with the published sequence of SA14 ( AF495589 ), the homology of the nucleotide sequence was 98% and the seven mutations resulting in amino acid substitutions at Leu 36 Ser, Leu107 Val, Ala167 Thr, Asn 230 Ser, Leu 340 Pro, Asn 430 Ile, Phe 448 Leu. Phylogenetic analysis of the E sequence of isolated strain classified it within genotype III of the JEV. The result of Western blotting indicated that the antigenicity of the protein was specific. Conclusions: The stable expression of the protein and the analysis of its antigenic specificity provide the foundation for developing the ELISA early stage diagnosis kit. Significance and Impact of the Study: As coating antigen, the recombinant E protein served a good source in the indirect ELISA method for the detection of JEV antibody.     

The interaction of alphavirus E1 protein with exogenous domain III defines stages in virus-membrane fusion

Alphaviruses such as Semliki Forest virus (SFV) are enveloped viruses that infect cells through a low-pH-triggered membrane fusion reaction mediated by the transmembrane fusion protein E1. E1 drives fusion by insertion of its hydrophobic fusion loop into the cell membrane and refolding to a stable trimeric hairpin. In this postfusion conformation, the immunoglobulin-like domain III (DIII) and the stem region pack against the central core of the trimer. Membrane fusion and infection can be specifically inhibited by exogenous DIII, which binds to an intermediate in the E1 refolding pathway. Here we characterized the properties of the E1 target for interaction with exogenous DIII. The earliest target for DIII binding was an extended membrane-inserted E1 trimer, which was not detectable by assays for the stable postfusion hairpin. DIII binding provided a tool to detect this extended trimer and to define a series of SFV fusion-block mutants. DIII binding studies showed that the mutants were blocked in distinct steps in fusion protein refolding. Our results suggested that formation of the initial extended trimer was reversible and that it was stabilized by the progressive fold-back of the DIII and stem regions.     

日本脑炎病毒(JEV)复制子表达载体的构建及其鉴定

在以往构建的JEV疫苗株SA14-14-2感染性克隆pBRkpn-JTF的基础上,构建了去除JEV结构区域基因(prM基因和E基因),保留非结构区域基因的复制子表达载体pCTCJEV、pCTMJEV,转染BHK-21细胞后,通过反转录PCR(RT-PCR)和间接免疫荧光实验(IFA)检测该载体的自主复制能力和蛋白表达情况,结果证实该载体在BHK-21细胞中能够自主复制并且表达非结构蛋白。进一步在该载体中插入报告基因EGFP,检测外源蛋白的表达情况,结果显示在转染复制子载体的24h后,荧光显微镜下能够看见绿色荧光蛋白的表达,阳性信号持续增强,能够维持10d左右,证实了构建的复制子载体pCTCJEV能够有效地表达外源蛋白,这为进一步建立以乙脑病毒复制子为基础的疫苗载体系统打下基础。